In a groundbreaking initiative unveiled at Arab Health 2025, Cleveland Clinic Abu Dhabi, part of the M42 Group, has partnered with BioTwin, a Canadian digital health startup and member of Hub71, to pilot virtual human twin technology for breast cancer screening.
BioTwin’s cutting-edge virtual twin technology integrates advanced data analytics, machine learning, and biological biomarkers to create highly detailed digital replicas of individual patients. These personalized virtual twins continuously analyze patient data to detect subtle changes that may indicate the early onset of diseases, including breast cancer. The collaboration with Cleveland Clinic Abu Dhabi aims to validate this innovative approach by creating unique patient profiles for enhanced early detection, reinforcing the UAE’s position at the forefront of global healthcare innovation.
Dr. Rafal Iskanderian, Staff Physician, General Surgery, Oncology Institute, Cleveland Clinic Abu Dhabi, emphasized the significance of this collaboration, stating:
“This partnership represents a major advancement in breast cancer screening, aligning with Cleveland Clinic Abu Dhabi’s commitment to deploying the latest health-tech innovations. By integrating virtual twin technology with our clinical expertise, we aim to enhance early detection, potentially saving lives and improving patient outcomes. The future of healthcare is being shaped right here at home.”
Louis-Philippe Noel, Founder and CEO of BioTwin, echoed this sentiment, noting:
“Our collaboration with Cleveland Clinic Abu Dhabi marks a defining moment for BioTwin. By combining our virtual twin technology with their world-class medical expertise, we are set to revolutionize breast cancer screening and elevate patient care.”
A High-Tech Collaboration Backed by Microsoft and Hub71
BioTwin is a participant in the Microsoft Entrepreneurship for Positive Impact initiative, which provides access to training, mentorship, Azure cloud credits, and partnership opportunities for startups addressing global challenges. The pilot will be powered by Microsoft Azure, underscoring the tech giant’s commitment to advancing AI-driven healthcare solutions.
Dr. David Rhew, Vice President and Global Chief Medical Officer, Microsoft Health and Life Sciences, highlighted the impact of this collaboration:
“This initiative showcases the transformative potential of startups working alongside established healthcare leaders. Through Microsoft Azure, we are accelerating the development and validation of technologies that will redefine patient care and outcomes.”
Ahmad Ali Alwan, CEO of Hub71, underscored Abu Dhabi’s growing influence in the HealthTech sector:
“We are proud to see Hub71 startups like BioTwin forging impactful partnerships that drive business growth and innovation. Abu Dhabi continues to be a leading launchpad for high-growth startups, especially in the healthcare sector, a key economic priority for the UAE.”
Strengthening Abu Dhabi’s Position in Healthcare Innovation
The Department of Health – Abu Dhabi has previously approved BioTwin’s technology for research purposes, paving the way for this innovative pilot. This partnership underscores Hub71’s role in fostering a thriving startup ecosystem, bridging cutting-edge technology with leading corporations and government institutions to drive breakthrough advancements in healthcare.
